Cargando…

Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN-α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients

BACKGROUND: Data on which to base definitive recommendations on the doses and duration of therapy for genotype 3 HCV/HIV-coinfected patients are scarce. We evaluated the efficacy of a lower peginterferon-α 2a dose and a shorter duration of therapy than the current standard of care in genotype 3 HCV/...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Cortés, Luis F., Ruiz-Valderas, Rosa, Jimenez-Jimenez, Luis, González-Escribano, María F., Torres-Cornejo, Almudena, Mata, Rosario, Rivero, Antonio, Pineda, Juan A., Marquez-Solero, Manuel, Viciana, Pompeyo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250391/ https://www.ncbi.nlm.nih.gov/pubmed/22235243 http://dx.doi.org/10.1371/journal.pone.0028115

Ejemplares similares

HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients
por: Rivero-Juarez, Antonio, et al.
Publicado: (2014)

Differential Effects of Viremia and Microbial Translocation on Immune Activation in HIV-Infected Patients Throughout Ritonavir-Boosted Darunavir Monotherapy
por: BenMarzouk-Hidalgo, Omar J., et al.
Publicado: (2015)

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2015)

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients
por: Rivero-Juárez, Antonio, et al.
Publicado: (2012)

Liver Fibrosis, Host Genetic and Hepatitis C Virus Related Parameters as Predictive Factors of Response to Therapy against Hepatitis C Virus in HIV/HCV Coinfected Patients
por: Corchado, Sara, et al.
Publicado: (2014)

Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study
por: López-Cortés, Luis F, et al.
Publicado: (2010)

Changes in immune activation in the T Cell compartments of HIV HCV coinfected patients during PEG IFN RBV treatment
por: Menard, Amélie, et al.
Publicado: (2012)

Long-term Persistent Elite HIV-controllers: The Right Model of Functional Cure
por: Tarancon-Diez, Laura, et al.
Publicado: (2018)

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
por: Gutierrez‐Valencia, Alicia, et al.
Publicado: (2018)

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis
por: Merchante, Nicolás, et al.
Publicado: (2015)

High-resolution anoscopy in HIV-infected men: Assessment of the learning curve and factors that improve the performance
por: Neukam, Karin, et al.
Publicado: (2019)

Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000-2010
por: de Felipe, Beatriz, et al.
Publicado: (2011)

Absolute CD4(+) T cell count overstate immune recovery assessed by CD4(+)/CD8(+) ratio in HIV-infected patients on treatment
por: Milanés-Guisado, Yusnelkis, et al.
Publicado: (2018)

Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population
por: López-Cortés, Luis F., et al.
Publicado: (2014)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

The ADE Display Application
por: Solero, Almudena
Publicado: (2003)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens
por: López-Cortés, Luis F., et al.
Publicado: (2016)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015)

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
por: Sandoughdaran, Saleh, et al.
Publicado: (2015)

No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2018)

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy
por: Neukam, Karin, et al.
Publicado: (2015)

Mesenchymal stromal cells in human immunodeficiency virus‐infected patients with discordant immune response: Early results of a phase I/II clinical trial
por: Trujillo‐Rodríguez, María, et al.
Publicado: (2020)

Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNα2a shows earlier viral decline than peg-IFNα2b in combination therapy with ribavirin
por: Fujino, Tatsuya, et al.
Publicado: (2011)

VDR rs2228570 Polymorphism Is Related to Non-Progression to AIDS in Antiretroviral Therapy Naïve HIV-Infected Patients
por: Jiménez-Sousa, María A., et al.
Publicado: (2019)

CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV
por: Lin, Chia-Chen, et al.
Publicado: (2017)

Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis
por: Jia, Zhifang, et al.
Publicado: (2012)

Novel CD28 antagonist mPEG PV1-Fab’ mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production
por: Papotto, Pedro Henrique, et al.
Publicado: (2017)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
por: Brochado, Óscar, et al.
Publicado: (2021)

Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses
por: Salgado, Maria, et al.
Publicado: (2018)

Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens
por: Wu, Fengping, et al.
Publicado: (2023)

Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial
por: Xu, Yan, et al.
Publicado: (2017)

Granulomatous mastitis due to coinfection with Histoplasma sp. and Paracoccidioides sp.: A case report
por: Merino-Alado, Rommie, et al.
Publicado: (2020)

Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4
por: Rizk, Hanan H., et al.
Publicado: (2016)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients
por: Bertol, Bruna C., et al.
Publicado: (2015)

Clinical Efficacy of PEG-IFNα-2a and PEG-IFNα-2b in the Treatment of Hepatitis B e Antigen-Positive Hepatitis B and Their Value in Improving Inflammatory Factors and Hemodynamics in Patients: A Comparative Study
por: Jia, Nina, et al.
Publicado: (2022)

No impact of IL28B polymorphisms on liver enzymes in patients coinfected with HIV and HCV
por: Fernández-Montero, JV, et al.
Publicado: (2010)

PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C
por: Markova, Antoaneta A., et al.
Publicado: (2014)

SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China
por: Li, Yanhua, et al.
Publicado: (2017)

Retracted: Clinical Efficacy of PEG-IFNα-2a and PEG-IFNα-2b in the Treatment of Hepatitis B e Antigen-Positive Hepatitis B and Their Value in Improving Inflammatory Factors and Hemodynamics in Patients: A Comparative Study
por: Longevity, Oxidative Medicine and Cellular
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rb8htp68pb66k96m6e09olauvg